Catalent has completed the acquisition of RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs). RheinCell’s iPSC tools, services and expertise offers the building blocks to industrialize iPSC-based cell therapies and complements Catalent’s existing iPSC process development and manufacturing capabilities.
 
Catalent plans to facilitate accelerated access to these high-quality iPSC banks by leveraging its broad and expanding network. This acquisition positions Catalent as a full value chain partner of choice for iPSC-based therapeutics with integrated solutions from plasmid DNA manufacturing to clinical supply.